88 related articles for article (PubMed ID: 14517846)
1. CD40 ligand is selectively expressed on CD4+ T cells and platelets: implications for CD40-CD40L signalling in atherosclerosis.
Büchner K; Henn V; Gräfe M; de Boer OJ; Becker AE; Kroczek RA
J Pathol; 2003 Oct; 201(2):288-95. PubMed ID: 14517846
[TBL] [Abstract][Full Text] [Related]
2. Co-stimulators CD40-CD40L, a potential immune-therapy target for atherosclerosis: A review.
Tian S; Wang Y; Wan J; Yang M; Fu Z
Medicine (Baltimore); 2024 Apr; 103(14):e37718. PubMed ID: 38579073
[TBL] [Abstract][Full Text] [Related]
3. Involvement of CD40-CD40L and ICOS-ICOSL in the development of chronic rhinosinusitis by targeting eosinophils.
Zhou A; Shi C; Fan Y; Zheng Y; Wang J; Liu Z; Xie H; Liu J; Jiao Q
Front Immunol; 2023; 14():1171308. PubMed ID: 37325657
[TBL] [Abstract][Full Text] [Related]
4. Binding of CD40L to Mac-1's I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis--but does not affect immunity and thrombosis in mice.
Wolf D; Hohmann JD; Wiedemann A; Bledzka K; Blankenbach H; Marchini T; Gutte K; Zeschky K; Bassler N; Hoppe N; Rodriguez AO; Herr N; Hilgendorf I; Stachon P; Willecke F; Duerschmied D; von zur Muhlen C; Soloviev DA; Zhang L; Bode C; Plow EF; Libby P; Peter K; Zirlik A
Circ Res; 2011 Nov; 109(11):1269-79. PubMed ID: 21998326
[TBL] [Abstract][Full Text] [Related]
5. Regulation of CD40 signaling in colon cancer cells and its implications in clinical tissues.
Zhou Y; Zhou SX; Gao L; Li XA
Cancer Immunol Immunother; 2016 Aug; 65(8):919-29. PubMed ID: 27262846
[TBL] [Abstract][Full Text] [Related]
6. Investigation of activation-induced markers (AIM) in porcine T cells by flow cytometry.
Moorton M; Tng PYL; Inoue R; Netherton CL; Gerner W; Schmidt S
Front Vet Sci; 2024; 11():1390486. PubMed ID: 38868498
[TBL] [Abstract][Full Text] [Related]
7. Role of inflammatory signaling pathways involving the CD40-CD40L-TRAF cascade in diabetes and hypertension-insights from animal and human studies.
Strohm L; Daiber A; Ubbens H; Krishnankutty R; Oelze M; Kuntic M; Hahad O; Klein V; Hoefer IE; von Kriegsheim A; Kleinert H; Atzler D; Lurz P; Weber C; Wild PS; Münzel T; Knosalla C; Lutgens E; Daub S
Basic Res Cardiol; 2024 Mar; ():. PubMed ID: 38554187
[TBL] [Abstract][Full Text] [Related]
8.
Cappelleri A; Canesi S; Bertola L; Capo V; Zecchillo A; Albano L; Villa A; Scanziani E; Recordati C
Vet Pathol; 2024 May; ():3009858241252409. PubMed ID: 38757523
[TBL] [Abstract][Full Text] [Related]
9. CD40L and Its Receptors in Atherothrombosis-An Update.
Michel NA; Zirlik A; Wolf D
Front Cardiovasc Med; 2017; 4():40. PubMed ID: 28676852
[TBL] [Abstract][Full Text] [Related]
10. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis.
Lievens D; Eijgelaar WJ; Biessen EA; Daemen MJ; Lutgens E
Thromb Haemost; 2009 Aug; 102(2):206-14. PubMed ID: 19652870
[TBL] [Abstract][Full Text] [Related]
11. Postoperative Pulmonary Hemodynamics and Systemic Inflammatory Response in Pediatric Patients Undergoing Surgery for Congenital Heart Defects.
Souza MFS; Penha JG; Maeda NY; Galas FRBG; Abud KCO; Carvalho ES; Thomaz AM; Castro CRP; Pereira J; Lopes AA
Mediators Inflamm; 2022; 2022():3977585. PubMed ID: 35075348
[TBL] [Abstract][Full Text] [Related]
12. Plasma Protein Profile of Carotid Artery Atherosclerosis and Atherosclerotic Outcomes: Meta-Analyses and Mendelian Randomization Analyses.
Lind L; Gigante B; Borné Y; Feldreich T; Leppert J; Hedberg P; Östgren CJ; Nyström FH; Sundström J; Ärnlöv J; Baldassarre D; Tremoli E; Veglia F; Hamsten A; O'Donnell CJ; Franceschini N; Orho-Melander M; Nilsson J; Melander O; Engström G; Mälarstig A
Arterioscler Thromb Vasc Biol; 2021 May; 41(5):1777-1788. PubMed ID: 33657885
[TBL] [Abstract][Full Text] [Related]
13. Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study.
Visvanathan S; Daniluk S; Ptaszyński R; Müller-Ladner U; Ramanujam M; Rosenstock B; Eleftheraki AG; Vinisko R; Petříková A; Kellner H; Dokoupilova E; Kwiatkowska B; Alten R; Schwabe C; Baum P; Joseph D; Fine JS; Padula SJ; Steffgen J
Ann Rheum Dis; 2019 Jun; 78(6):754-760. PubMed ID: 30902820
[TBL] [Abstract][Full Text] [Related]
14. The association of CD40 polymorphism (rs1883832C/T) and soluble CD40 with the risk of systemic lupus erythematosus among Egyptian patients.
Mousa TG; Omar HH; Emad R; Salama MI; Omar W; Fawzy M; Hassoba HM
Clin Rheumatol; 2019 Mar; 38(3):777-784. PubMed ID: 30374748
[TBL] [Abstract][Full Text] [Related]
15. Start a fire, kill the bug: The role of platelets in inflammation and infection.
Deppermann C; Kubes P
Innate Immun; 2018 Aug; 24(6):335-348. PubMed ID: 30049243
[TBL] [Abstract][Full Text] [Related]
16. Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE.
Dörner T; Lipsky PE
Nat Rev Rheumatol; 2016 Nov; 12(11):645-657. PubMed ID: 27733759
[TBL] [Abstract][Full Text] [Related]
17. Are Platelets Cells? And if Yes, are They Immune Cells?
Garraud O; Cognasse F
Front Immunol; 2015; 6():70. PubMed ID: 25750642
[TBL] [Abstract][Full Text] [Related]
18. Tight control - decision-making during T cell-vascular endothelial cell interaction.
Firner S; Onder L; Nindl V; Ludewig B
Front Immunol; 2012; 3():279. PubMed ID: 22969771
[TBL] [Abstract][Full Text] [Related]
19. New steroidal glycosides isolated as CDL inhibitors of activated platelets.
Chen H; Ou W; Wang G; Wang N; Zhang L; Yao X
Molecules; 2010 Jun; 15(7):4589-98. PubMed ID: 20657379
[TBL] [Abstract][Full Text] [Related]
20. The effect of hormone therapy and tibolone on serum CD40L and ADAM-8 in healthy post-menopausal women.
Lambrinoudaki I; Karaflou M; Kaparos G; Grigoriou O; Alexandrou A; Panoulis C; Logothetis E; Creatsa M; Christodoulakos G; Kouskouni E
J Endocrinol Invest; 2010 Nov; 33(10):720-4. PubMed ID: 20436265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
